---
title: "BeOne Medicines hits record high in overnight trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305242358.md"
description: "BeOne Medicines rose 1.95% to US$428.17. Up 13.34% over five sessions and up 40.94% YTD."
datetime: "2026-11-12T02:48:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305242358.md)
  - [en](https://longbridge.com/en/news/305242358.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305242358.md)
generator: "portal-rs"
---

# BeOne Medicines hits record high in overnight trading

BeOne Medicines (ONC.US) rose nearly **2%** in overnight trading to a record high of **$428.17**.

The stock is up 13.34% over the past five sessions and up 40.94% year to date. It sits 68.61% above its 52-week low of US$253.94.

The Nasdaq Composite is down 1.05% over the past five sessions and up 9.57% year to date.

China's Center for Drug Evaluation proposed on Nov. 9 to grant priority review to daraxonrasib tablets for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or are unsuitable for multi-drug combination regimens.

Separately, the company reported first-nine-month revenue of 34.993 billion yuan, up 26.8% from a year earlier, while net income attributable to shareholders surged 431.8% to 6.055 billion yuan. Driven by strong sales of its core product Brukinsa, BeOne raised its full-year 2026 revenue guidance to $6.9 billion to $7.0 billion.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)

## Related News & Research

- [BeOne Medicines: Five solid-tumor programs advance as strong cash flow funds continued pipeline investment](https://longbridge.com/en/news/305810947.md)
- [Why BeOne Medicines Stock Is In Focus After Earnings Beat And Raised Guidance](https://longbridge.com/en/news/304730912.md)
- [BeOne stock breaks out with visions of 177% earnings growth. This telltale clue bodes well.](https://longbridge.com/en/news/302773305.md)
- [Cipher Digital Hovers Near Flatline After Anthropic's $83 IPO Pricing](https://longbridge.com/en/news/306148104.md)
- [BeOne Medicines (ONC) Gets FDA Priority Review For First Line Lymphoma Regimen](https://longbridge.com/en/news/304614462.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**